SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (date of earliest event reported) July 13, 2004
SALIX PHARMACEUTICALS, LTD.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
| 000-23265 | 94-3267443 | |
| (Commission file Number) | (IRS Employer ID Number) |
| 8540 Colonnade Center Drive, Suite 501, Raleigh, North Carolina 27615 | ||
| (Address of principal executive offices) (Zip Code) | ||
Registrant’s telephone number, including area code (919) 862-1000
Item 5. Other Events and Regulation FD Disclosure
On July 13, 2004, Salix Pharmaceuticals, Ltd. issued a press release announcing that the Company began shipping XIFAXAN™ (rifaximin) tablets 200 mg to wholesale distributors across the United States on Monday, July 12. A copy of this press release is attached.
Item 7. Financial Statements and Exhibits.
| (c) | Exhibits |
| Exhibit No. | Description | |
| 99.1 | Press release dated July 13, 2004 of Salix Pharmaceuticals, Ltd. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| SALIX PHARMACEUTICALS, LTD. | ||||
| Date: July 13, 2004 | By: | /s/ Adam C. Derbyshire | ||
| Adam C. Derbyshire | ||||
| Senior Vice President and Chief Financial Officer | ||||
